contribution of cardiovascular disease
burden of cardiovascular disease
biomarker value of non-coding RNAs
non-coding RNA modulators
Biomarker Potential of long non-coding RNAs
disease-relevant experimental
advanced forms of aneurysm disease
human morbidity
post-transcriptional regulatory milieu
cardiovascular homeostasis
post-transcriptional inhibitors of gene expression
NATs influences aneurysm progression
recognizing patients
human diseased tissue samples
unique human plasma material
therapeutic strategies
antisense capabilities
ruptured aneurysms
vascular system
development of novel diagnostic
abdominal aortic aneurysms
natural antisense transcriptsâ€™
novel crucial regulators of smooth muscle cell survival
targeting CTPS1
local delivery mechanisms
carotid stenosis
microRNAs
NUDT6
ones
transcriptomic profiling techniques
atherosclerotic plaque vulnerability
fibroblast growth factor
stents
LDLR
rodents
drug eluting balloons
collective work of multiple research groups
FGF2
models
subsequent stroke
studies
access
SLFNL-AS1
inhibition
mortality
current proposal
pathophysiological characteristics
etiology
translational feasibility
mini-pigs
future risk of rupture
response
extraordinary efforts
aging European society
findings
focus
attention